| First Author | Ha HL | Year | 2020 |
| Journal | J Invest Dermatol | Volume | 140 |
| Issue | 1 | Pages | 143-151.e3 |
| PubMed ID | 31252033 | Mgi Jnum | J:285816 |
| Mgi Id | MGI:6387672 | Doi | 10.1016/j.jid.2019.06.127 |
| Citation | Ha HL, et al. (2020) IL-20-Receptor Signaling Delimits IL-17 Production in Psoriatic Inflammation. J Invest Dermatol 140(1):143-151.e3 |
| abstractText | IL-17 cytokines, in particular IL-17A, are critical effectors in psoriasis. Antibodies that block IL-17A are highly efficacious in treating psoriasis. Likewise, disruption of IL-17 cytokines signaling, such as via the loss of the adaptor CIKS/Act1, ameliorates inflammation in mouse models of psoriasis. IL-17A promotes a cascade of effects, including the robust production of IL-19 in both humans and mice. IL-19, along with IL-20 and IL-24, signal via IL-20 receptors and comprise a subgroup within the IL-10 cytokine family. The role of these three cytokines in psoriasis is unresolved. They have been linked to inflammatory processes, including psoriatic pathology, but these cytokines have also been reported to suppress inflammation in other contexts. In this study, we demonstrate that signaling via IL-20 receptors, including in response to IL-19, delimited aspects of imiquimod-induced psoriatic inflammation. IL-20 receptor signaling suppressed the dermal production of the CCL2 chemokine and thereby reduced CCL-2-driven infiltration of inflammatory cells into the dermis, including IL-17A-producing gammadeltaT cells. This constitutes a negative feedback, since IL-17A strongly induces IL-19 in keratinocytes. The effects of IL-17 cytokines in this inflammatory setting are dynamic; they are central to the development of both dermal and epidermal hallmarks of psoriasis but also initiate a path to mitigate inflammatory damage. |
